Scienture Begins July Shipments of High-Dose Naloxone Spray REZENOPY™ Ahead of August Launch — Scienture Holdings, Inc.

Event summary

Scienture Holdings, Inc. has completed manufacturing of commercial launch inventory for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. wholesalers in July.
The product is expected to become commercially available in August, marking a significant milestone in Scienture's commercial strategy.
REZENOPY™ is the highest-dose FDA-approved naloxone hydrochloride nasal spray, designed for emergency treatment of opioid overdoses.
The U.S. naloxone market generated approximately $144 million in annual sales across 9.8 million units (IQVIA data, MAT April 2026).
Scienture has expanded payer access with potential coverage reaching more than 100 million covered lives.

The big picture

Scienture's commercialization of REZENOPY™ comes amid a persistent opioid crisis in the U.S., with overdoses remaining a leading cause of preventable drug-related deaths. The launch represents Scienture's continued expansion into specialty pharmaceuticals, following its October 2025 introduction of Arbli™. With potential coverage reaching over 100 million lives and a substantial market opportunity, REZENOPY™ could significantly bolster Scienture's revenue streams if it gains traction among key stakeholders in the opioid reversal space.

What we're watching

Market Penetration: How Scienture will leverage its expanded payer access to drive adoption of REZENOPY™ among pharmacies, healthcare providers, and first responders.
Competitive Dynamics: Whether REZENOPY™'s higher dose can differentiate it in a market with existing naloxone treatments and capture significant share of the $144 million U.S. naloxone market.
Execution Risk: The pace at which Scienture can scale production and distribution to meet demand, following the successful launch of its previous product Arbli™ in October 2025.